Australian Idiopathic Pulmonary Fibrosis Registry

The Australian IPF Registry has been established by Lung Foundation Australia and is now recruiting.

What is IPF?

Idiopathic Pulmonary Fibrosis, commonly shortened to IPF, is a condition that causes persistent and progressive scarring of the tiny air sacs (alveoli) in the lungs. Click here to find out more about IPF.

Why develop an Australian IPF Registry?

High resolution computed tomography scanning has led to earlier diagnosis of IPF, providing physicians with the potential for early intervention of this severe and complex lung condition. As a rare lung disease no single Australian centre has an adequate patient population to facilitate robust research.

How has the Australian IPF Registry been developed?

Lung Foundation Australia has established the Australian IPF Registry with the generous support of a number of philanthropic families and the Royal Hobart Hospital Research Foundation. Financial support for the Australian IPF Registry is also proudly provided in the form of unrestricted educational grants by various sponsors (see acknowledgment section below).


Above: Australian IPF Registry Steering Committee members. From L to R. Back Haydn Walters, Richard Wood-Baker, Chris Zappala, Samantha Ellis, Peter Hopkins , and front, Yuben Moodley, Ian Glaspole, Sacha Macansh (secretariat), Sally Chapman,  Annabelle Mahar, Tamera Corte, Nicole Goh. Registry Steering Committee members not in photo are Paul Reynolds, William Darbishire and Wendy Cooper.

An expert team of Principal Investigators from every State and other Steering Committee members have developed the Australian IPF Registry, together with the Lung Foundation Australia. The Rare Lung Disease National Advisory Committee (previously known as PIVOT) provides over arching governance to the Registry. A global network has been established with support from the Royal Brompton Hospital in the UK and the University of California, San Francisco in the USA. Registry data sets have been designed specifically to complement and build on the experience and expertise of these recognised international centres.

What benefits does the Australian IPF Registry provide?

The Australian IPF Registry provides many benefits:

  • A unique platform for epidemiological and clinical research
  • Improved recruitment into clinical trials
  • Increased IPF disease awareness and improved tertiary referral
  • Improved patient understanding and support networks
  • Improved Australian and international IPF research collaboration
  • Expert specialists provide feedback on HRCT scans and/or surgical biopsy slides.


How can health professionals be involved?

Join AUS IPF-net – the AUS IPF-net is a special interest group for all health professionals and researchers established by the Registry. As a member you will:

    • Receive regular e-newsletters keeping you up to date with:
    • Registry progress and research findings
    • IPF trials that may be of interest to your patients
    • Global studies and new findings on IPF.
    • Be invited to symposia and meetings on IPF and Interstitial Lung Disease.

To join contact the Registry Project Manager


Creating the Australian IPF Registry establishes a unique research resource for all clinical and research collaborators. During the initial project period the Registry expects to expand to 700 patients. Registry data may potentially be used to address a number of types of research questions in epidemiology, medical and drug trial research.

In the future tissue studies are planned. All patients are currently being consented for a blood sub-study and funding to support this initiative is being sought.

The Registry Steering Committee is keen to consider applications to use Registry data for research.

For further information on this process or for a copy of the Registry publications policy please contact the Registry Project Manager.


European Respiratory Journal (2017) 50: 1700168

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis

Glaspole I.G, Watson A.L, Allan H, Chapman S, Cooper W.A, Corte T.J,Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y,  Reynolds P.N, Ryerson C.J, Walters E.H,  Zappala CJ and Holland A.E.

Respirology (2017) doi: 10.1111/resp.12989

Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry

Glaspole I.N,  Chapman S.A.,  Cooper W.A.,  Ellis S.J.,  Goh N.S., Hopkins P.M, Macansh S., Mahar A., Moodley Y.P., Reynolds P.N., Walters E.H.,  Zappala C.J.  and Corte T.J. 

European Respiratory Journal (2017) 49 1601592

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry

Jo H.E, Glaspole I., Grainge C., Goh N., Hopkins P.M.A, Moodley Y., Reynolds P.N.,  Chapman, S.E. Walters H.E, Zappala C., Allan A., Keir G.J., Hayen A., Cooper W.A., Mahar A.M, Ellis S., Macansh S., and Tamera J. Corte

Respirology (2014) 19, 1088–1091

Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project.

Moodley, Y., Goh, N., Glaspole, I., Macansh, S., Walters, ES., Chapman, S., Hopkins, P., Reynolds, PN., Zappala, C., Cooper, W., Mahar, A., Ellis, S., McCormack, S., Darbishire, W., Wood-Baker, R., Corte, TJ. (For the Australian IPF Registry Steering Committee).



Useful IPF References and Guidelines

American Journal of Respiratory and Critical Care Medicine Volume 192 Number 2, pp 238-248, Jul 15, 2015

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline

Raghu G., Rochwerg B., Zhang Y., Cuello Garcia CA., Azuma A., Behr J.,  Brozek JL., Collard HR., Cunningham W., Homma S., Johkoh T., Martinez FJ.,  Myers J., Protzko SL., Richeldi L., Rind D., Selman M., Theodore A., Wells AU., Hoogsteden H., and Schunemann HS; on behalf of the ATS, ERS, JRS, and ALAT


Project manager – Sacha Macansh
Telephone: +61 (0)2 9515 3996
Facsimile: +61 (0)2 9515 8196


The Australian IPF Registry is proudly sponsored by:
Foundation Partners
Project Partners
An initiative of:
Rare Lung Disease National Advisory Committee (previously known as PIVOT)


Lung Foundation Australia would also like to acknowledge and thank the Royal Hobart Hospital Research Foundation for its generous support in establishing the Australian IPF Registry alongside the members of the Registry Radiology and Histopathology review panels.

The Australian IPF Registry gratefully acknowledges the in- kind support of:

Alfred Medical Imaging, NSW

Alfred Health, Melbourne, Victoria

Central Adelaide Local Health Network Inc. Royal Adelaide Hospital

Institute for Respiratory Health, WA

Royal Prince Alfred Hospital, Camperdown NSW

University of Tasmania, Hobart, TAS.


The Australian IPF Registry gratefully acknowledges the generous contribution of the members of the Registry Radiology and Histopathology review panels.

Radiology Review panel

Dr Samantha Ellis
Dr Samuel R. McCormack
Dr Stefan B. Heinze
Dr Anne Miller
Dr Bernard Ng
Dr Hannah C. Rouse

Histopathology Review panel

A/Professor Wendy Cooper
Dr Annabelle M. Mahar
Dr Edwina Duhig
Dr David B. Godbolt
Professor Douglas Henderson
A/Professor Sonja Klebe